Results 1 to 10 of about 178,854 (310)

APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants [PDF]

Frontiers in Virology, 2022
The V179I substitution in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is selected in humans or mouse models treated with certain nonnucleoside reverse transcriptase inhibitors (NNRTIs).
Richa Dwivedi, Youya Wang, Christopher Kline, Douglas K. Fischer, Zandrea Ambrose   +4 more
doaj   +2 more sources

Nucleoside Reverse Transcriptase Inhibitor Exposure Is Associated with Lower Alzheimer’s Disease Risk: A Retrospective Cohort Proof-of-Concept Study [PDF]

Pharmaceuticals
Brain somatic gene recombination (SGR) and the endogenous reverse transcriptases (RTs) that produce it have been implicated in the etiology of Alzheimer’s disease (AD), suggesting RT inhibitors as novel prophylactics or therapeutics.
Tiffany W. Chow, Mark Raupp, Matthew W. Reynolds, Siying Li, Gwendolyn E. Kaeser, Jerold Chun   +5 more
doaj   +2 more sources

Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week. [PDF]

J Acquir Immune Defic Syndr, 2022
Schürmann D, Jackson Rudd D, Schaeffer A, De Lepeleire I, Friedman EJ, Robberechts M, Zhang S, Liu Y, Kandala B, Keicher C, Däumer M, Hofmann J, Grobler JA, Stoch SA, Iwamoto M, Ankrom W.   +15 more
europepmc   +2 more sources

Nucleoside and non-nucleoside reverse transcriptase inhibitor drugs (NRTIs and NNRTIs) are capable of binding Chandipura virus polymerase protein (L) and inhibit virus replication. [PDF]

Virusdisease
Mandal D, Pandey D, Sarkar DP, Kumar M.
europepmc   +3 more sources

Reverse transcriptase inhibition: a way to defeat HIV

HIV & AIDS Review. International Journal of HIV-Related Problems, 2022
Human immunodeficiency virus (HIV) induces disease in humans that is known as AIDS (acquired immunodeficiency syndrome). First AIDS cases were registered in 1981, and later, types of HIV infection, such as HIV-1 and HIV-2 were identified.
Vikas Kumar, Harish Joshi, I. Pandey
doaj   +1 more source

Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal. [PDF]

PLoS ONE, 2012
IntroductionCurrent Portuguese HIV treatment guidelines recommend initiating antiretroviral therapy with a regimen composed of two Nucleoside Reverse Transcriptase Inhibitors plus one Non-nucleoside Reverse Transcriptase Inhibitor (2NRTI+NNRTI) or two ...
Filipa Aragão, José Vera, Inês Vaz Pinto   +2 more
doaj   +1 more source

Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions With HIV-1 Reverse Transcriptase

Frontiers in Molecular Biosciences, 2022
Reverse transcriptase (RT) from the human immunodeficiency virus continues to be an attractive drug target for antiretroviral therapy. June 2022 will commemorate the 30th anniversary of the first Human Immunodeficiency Virus (HIV) RT crystal structure ...
Kathleen M. Frey, Nicole Bertoletti, Albert H. Chan, Joseph A. Ippolito, Mariela Bollini, Krasimir A. Spasov, William L. Jorgensen, Karen S. Anderson, Karen S. Anderson   +8 more
doaj   +1 more source

Effect of Antiretroviral Therapy on Circulating Lipid Levels in Human Immunodeficiency Virus Infected Patients: A Cross-sectional Study [PDF]

Journal of Clinical and Diagnostic Research, 2022
Introduction: The antiretroviral drugs have improved the quality and extent of life of Human Immunodeficiency Virus (HIV) infected patients, yet like any other long-term medication, these are known to cause several adverse effects.
RN Devaki, Hasit Kumar D Lad, Rana Neetaben Maheshchandra, N Chandrika   +3 more
doaj   +1 more source

Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors.

PLoS ONE, 2020
BackgroundChoice of initial antiretroviral therapy regimen may help children with HIV maintain optimal, continuous therapy. We assessed treatment-naïve children for differences in time to treatment disruption across randomly-assigned protease inhibitor ...
Dwight E Yin, Christina Ludema, Stephen R Cole, Carol E Golin, William C Miller, Meredith G Warshaw, Ross E McKinney, PENPACT-1 (PENTA 9 / PACTG 390) Study Team   +7 more
doaj   +1 more source

Correction: A new potent HIV-1 reverse transcriptase inhibitor: A synthetic peptide derived from the interface subunit domains. [PDF]

J Biol Chem, 2019
Morris MC, Mery J, Heitz F, Goody RS, Divita G.   +4 more
europepmc   +3 more sources